Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors | MicrobiomeTrials← Back to trialsNCT04140500
Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2019-11-11Est. Completion: 2027-06-30
Enrollment target: 170 participants Locations- Rigshospitalet, København Ø, Denmark
- Odense Universitetshospital, Onkologisk Afdeling R, Odense C, Denmark
- LLC Arensia Explorer Medicine, Tbilisi, Georgia
- Hadassah University Hospital - Ein Kerem, Jerusaelm, Israel
- Rabin MC, Petah Tikva, Israel
- Chaim Sheba medical center, Oncology division, Ramat Gan, Israel
- Hospital Civil de Guadalajara Fray Antonio Alcalde, Guadalajara, Jalisco, Mexico
- Inst. Nacional de Cancerología, Mexico City, Mexico CITY (federal District), Mexico
- Consultorio Médico Jordi Guzmán Casta, Querétaro City, Querétaro, Mexico
- National University Hospital, Singapore, Singapore
- National Cancer Centre, Singapore, Singapore
- Seoul National University Bundang Hospital, Seongnam-si, South Korea
- Severance Hospital, Yonsei University Health System, Seoul, South Korea
- Asan Medical Center, Seoul, South Korea
- Clinica Universitaria de Navarra, Pamplona, Navarre, Spain
- Vall d?Hebron Institute of Oncology (VHIO), Barcelona, Barcelona, Spain
Other microbiome trials you might be interested in
Advanced Solid Tumor
The purpose of this study is to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary …
Birmingham, United StatesEst. completion Nov 1, 2028
Very Rare TumorsVery Rare CancersOther Solid TumorsSolid TumorPediatric Rare Tumors
Background:
All childhood cancers are rare, but some are called very rare. Very rare cancers are diagnosed in 2 or fewe…
Bethesda, United StatesEst. completion Apr 1, 2035
Clinica Universidad de Navarra Madrid, Madrid, SpainSTART Madrid-FJD, Hospital Fundacion Jimenez Diaz, Madrid, SpainSTART Madrid. Centro Integral Oncologico Clara Campal, Madrid, SpainAdana City Hospital, Medical Oncology, Adana, Turkey (Türkiye)Ankara City Hospital, Ankara, Turkey (Türkiye)Hacettepe Uni Medical Faculty Hospital, Sihhiye/Ankara, Turkey (Türkiye)Ankara Abdurrahman Yurtaslan Oncology Training and Research Hospital Phase 1 Center, Yen?mahalle, Turkey (Türkiye)Queen Elizabeth Hospital, Birmingham, United KingdomChristie Hospital NHS Trust, Manchester, United KingdomNon-Small Cell Lung Cancer (NSCLC)
The primary objectives are to compare progression-free survival (PFS) and overall survival (OS) in participants who rece…
Santa Barbara, United StatesEst. completion Jun 30, 2027